Podcasts about wakelee

  • 32PODCASTS
  • 98EPISODES
  • 22mAVG DURATION
  • ?INFREQUENT EPISODES
  • Dec 11, 2023LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about wakelee

Latest podcast episodes about wakelee

ReachMD CME
Keeping Pace in Lung Cancer - Breaking Barriers: Advances in Treating EGFR Exon 20 Insertions in NSCLC

ReachMD CME

Play Episode Listen Later Dec 11, 2023


CME credits: 0.25 Valid until: 11-12-2024 Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-lung-cancer-breaking-barriers-advances-in-treating-egfr-exon-20-insertions-in-nsclc/16082/ We now have FDA approved targeted therapies to treat NSCLC with EGFR exon 20 insertion mutations. Drs. Wakelee and Bazhenova discuss the most current data on both approved therapies and drugs in development.=

Oncology Times - OT Broadcasts from the iPad Archives
ASCO 2023: Neoadjuvant Pembrolizumab Brought Big Benefit in Early-Stage Non-Small Cell Lung Cancer with Heather A. Wakelee, MD, FASCO

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jun 30, 2023 11:05


Non-small cell lung cancer was one of the big topics at the 2023 ASCO Annual Meeting where Heather Wakelee, MD, FASCO, Professor of Medicine and Chief of the Division of Oncology at Stanford University in California, was overheard reminding a junior cancer doctor that the only adjuvant therapy for lung cancer had been chemotherapy just a couple of decades previously. Now, a plethora of targeted therapies are available, and Wakelee reported a big improvement in outcome from one of them—pembrolizumab—used both before and after surgery in early Stage II and III disease (mostly Stage III). “These results indicate perioperative pembrolizumab given in combination with chemotherapy prior to surgery and for up to one year as a single agent after surgery led to significant improvement in event-free survival (defined by local progression precluding definitive surgery, recurrence, or death) with a strong trend towards improvement in overall survival. These results indicate peri-operative pembrolizumab significantly improves outcomes for patients with potentially resectable Stage II-III NSCLC,” said Wakelee. After her talk at ASCO, she discussed her group’s findings with OncTimesTalk correspondent, Peter Goodwin.

The Steve Driscoll Show
Wakelee: A Band Out Of Brooklyn

The Steve Driscoll Show

Play Episode Listen Later Jun 22, 2023 73:38


Wakelee is a band out of Brooklyn consisting of twins Alex and David Bulmer and Elliot Schiang. I found them because of their funny videos on tiktok but they make dope music too Checkout their debut album Wakelee now.

HiddenTracks
HiddenTrack #146 WAKELEE (Alex,David, and Elliot)

HiddenTracks

Play Episode Listen Later May 11, 2023 72:14


On this week's episode we meet up with the Brooklyn based band WAKELEE. Wakelee consists of identical twins Alex (vocals/guitar) and David Bulmer (drums) and Elliot Shiang (vocals/bass). They met at a friend's show in New York and immediately bonded over Halal food and music. They have since released an EP, a healthy batch of emo-tinged singles, and recently released their self-titled debut album, produced by Brian DiMeglio (Bartees Strange, Superbloom, Grandad) in April 2023. Join Alex, David, Elliot and I as we throw on some “Mood Rings” while we go on a “Nighttime Car Ride” to the life “Arcade.” WAKELEE - “Wakelee”      OUT NOW!!!!!!Thanks for listening!!! Please Follow us on Instagram @hiddentracks99

The Music Authority LIVE STREAM Show
May 9, 2023 Tuesday Hour 2

The Music Authority LIVE STREAM Show

Play Episode Listen Later May 9, 2023 59:53


Plumber here yesterday to fix the things that didn't pass on the FOUR POINT INSPECTION for a lower homeowner's premium.  New shut off valves for all the sinks and the master bath toilet!  They were severely corroded!  Unless you need to shut them off, do you really ever LOOK at them?  Inspecter back tonight!  Hope we pass this time!    The Music Authority Podcast...listen, like, comment, download, share, repeat…heard daily on Podchaser, Deezer, Amazon Music, Audible, Listen Notes, Google Podcast Manager, Mixcloud, Player FM, Stitcher, Tune In, Podcast Addict, Cast Box, Radio Public, and Pocket Cast, and APPLE iTunes!  Follow the show on TWITTER JimPrell@TMusicAuthority!  Please, are you listening? Please, are you sharing the podcast?  Please, has a podcast mention been placed into your social media?  How does and can one listen in? Let me list the ways...*Podcast - https://themusicauthority.transistor.fm/   The Music Authority Podcast!  Special Recorded Network Shows, too!  Different than my daily show! *Radio Candy Radio Monday Wednesday, & Friday 7PM ET, 4PM PT*Rockin' The KOR Tuesday, Wednesday, and Thursday at 7PM UK time, 2PM ET, 11AM PT  www.koradio.rocks*Pop Radio UK Friday, Saturday, & Sunday 6PM UK, 1PM ET, 10AM PT!  *The Sole Of Indie  https://soleofindie.rocks/  Monday Through Friday 6-7PM EST!May 9, 2023, Tuesday, row two…@Mark Johnson & Ramírez Exposure - 04 - When Worlds Collide [Tuning On The Century, Vol 2 (Happy Sparrow)]Joe Dilillo Music - 1 Loser Girl [Superhero Star]The Raging Teens - 05 - That's How I Like It [Rum Bar Rockin' Sampler- Viva Las Vegas 26] (Rum Bar Records)Tony Valentino of the Standells - 01 Try It [Dirty Water Revisited] (Big Stir Records)Damien Binder - 02 Here It Is [Bright Side]Jeremy Porter and The Tucos - 12 Hummingbird Heartbeat [Candy Coated Cannonball]@Adventure Playground - 9 New Plan(et) [Alright Already]The Streetwalkin' Cheetahs - Victim Of The Service Industry [April 2023 Audio Jukebox] (Rum Bar Records)Norwegian Soft Kitten - 10 Eyes Closed [On Loan From The Universe]Emperor Penguin - 09 - Blink [Corporation Pop!] (koolkatmusik.com)@Wakelee - 01 Plinko [Wakelee] (@Bok Choy LLC)@CARUSO - 15 The Long-Haired Girl (1982 Demo Remix) [In the Face 35th Anniversary Deluxe] (Dave Caruso)Kevin Robertson - 07 Wander On [Magic Spells Abound] (Futureman Records)Dolph Chaney - 08 Sideless World [This Is Dolph Chaney] (Big Stir Records)John Wayne Supermarket - 12 Assis La [Les Plus Grands Succès] (Twisted Soul Records)D-Tension - 05 - Other Side of The Road [Tales From The Pub] (Red on Red Records)Paul Callan - 5.Broken birds [Over My Wishes]

Research To Practice | Oncology Videos
Non-Small Cell Lung Cancer | Heather Wakelee, MD

Research To Practice | Oncology Videos

Play Episode Listen Later May 1, 2023 46:32


Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 1: Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) without an Actionable Mutation — Dr Heather Wakelee CME information and select publications

Chris Collins Show
Episode 109: OFF THE FRET with Brooklyn, New York Indie Emo Rock band WAKELEE

Chris Collins Show

Play Episode Listen Later Apr 21, 2023 49:18


OFF THE FRET, MORE MUSIC, MORE MUSIC TALK! If you're like ME – MUSIC is everything! Since day one it's been a passion of mine to create an opportunity to showcase amazing up-and-coming artists. The CHRIS COLLINS SHOW has interviewed some of the most incredible international and national bands out there—from Finland, the Philippines, India and UK—to NY, LA, Texas and Nashville—you name it. We are so fortunate to have this outlet to show you guys some of the most talented musicians out there today! There's no other medium that brings people together like LIVE MUSIC. Join me and listen to OFF THE FRET podcast. What's Good!? It's Chris from the Chris Collins Millennial Talk Show. Featuring Brooklyn trio, Wakelee, setting the tone with their debut self titled album “Wakelee”. Lyrics that explore the complexities of human emotion. Joins, Off The Fret more music, more music talk. https://www.wakeleemusic.com

OBR Peer-Spectives
The Best First Step in Metastatic NSCLC Care

OBR Peer-Spectives

Play Episode Listen Later Mar 10, 2023 9:13


With more than 10 known driver mutations in non-small cell lung cancer (NSCLC), testing is ever more critical, says Heather Wakelee, MD, division chief of medical oncology at Stanford University and president of the International Association for the Study of Lung Cancer. Listen as she and Peer-Spectives host Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology Oncology at Cedars-Sinai Cancer, talk about how she manages patients with metastatic disease or those who need adjuvant treatment, when she starts targeted therapy or immunotherapy, and more. “We can drastically change the course of disease for a patient by giving them the appropriate targeted treatment. So that testing is so critical,” Dr. Wakelee said.

Headliners
WAKELEE • Headliners #43

Headliners

Play Episode Listen Later Feb 22, 2023 12:51


On this episode of Headliners, Greg sits down with WAKELEE to talk about their upcoming self-titled album (OUT 14 APRIL).Formed in Brooklyn in 2019 by Bulmer, his identical twin brother David (drums) and Elliot Shiang (vocals/bass), they met at a friend's show in NYC and immediately bonded over Halal food and indie music. The trio has since released an EP, a healthy batch of emo-tinged singles, including the recently released tracks "Mood Rings," "Everything Under The Sun" and "Outside."CONNECT WITH WAKELEELinktree - Spotify - Instagram - TikTokSUPPORT THIS SHOW

Chris Collins Show
Episode 1405: Brooklyn Indie/Emo Trio, Wakelee

Chris Collins Show

Play Episode Listen Later Feb 17, 2023 34:47


Brooklyn Emo band Wakelee joins STRIKE A CHORD to discuss their upcoming self-titled album, Wakelee. We all saw it and we need to address it. What happened to Rihanna's Super Bowl 2023 HalfTime show? The performance was lackluster at best. BUT what did Howard Stern say that has everyone getting their twitter accounts cancelled—Wakelee has some sage advice for live performances! Alex (vocals/guitar) and David (drums) are identical twins and the triplet that went wrong is Elliot (vocals/bass)—so how do some Jersey bros link up with an Oregon player? This is a first! Urban Dictionary doesn't have a definition for Wakelee. BUT it's the perfect opportunity for the band to provide a backstory on how they named their band—although it's the last place you would expect. The feeling of not knowing how to feel after something bad happens is spot on for Wakelee's single “Mood Rings.” Sometimes we can be a "tin can"—having difficulty processing emotions and expressing feelings is confusing. Should I be angry, sad, mad, happy or glad. Is that profound enough or am I in Oz? Having an identical twin has some advantages. There's a world of possibilities where we can swap roles at any time. BUT does that work with relationships? Enoughs, enough! Time to get this album out and we can't wait to hear what Wakelee delivers. Follow, support and listen: https://www.wakeleemusic.com

MedEdTalks - Oncology
Updates in IO for Advanced NSCLC – Options for First-line Treatment and Management of Progressive Disease With Drs. Laurie Carr and Heather Wakelee

MedEdTalks - Oncology

Play Episode Listen Later Jan 4, 2023 18:58


MedEdTalks - Oncology
Updates on the Use of Neoadjuvant and Adjuvant IO in Patients With NSCLC With Drs. Laurie Carr and Heather Wakelee

MedEdTalks - Oncology

Play Episode Listen Later Jan 4, 2023 15:48


Oncology Today with Dr Neil Love
Management of Localized Non-Small Cell Lung Cancer with Dr Heather Wakelee

Oncology Today with Dr Neil Love

Play Episode Listen Later Sep 26, 2022 40:34


Dr Heather Wakelee from Stanford Cancer Institute in Palo Alto, California, discusses the management of localized non-small cell lung cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayLocalizedNSCLC22).

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Sta

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 24, 2022 68:54


Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Sta

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 24, 2022 68:54


Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Sta

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 24, 2022 68:52


Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Sta

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 24, 2022 68:52


Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Sta

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 24, 2022 68:52


Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Sta

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jan 24, 2022 68:54


Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Sta

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 24, 2022 68:54


Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Sta

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 24, 2022 68:52


Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

Lung Cancer Considered
Meet Our President and President Elect - Heather Wakelee and Paul Van Schil

Lung Cancer Considered

Play Episode Listen Later Sep 7, 2021 42:16


In this episode of Lung Cancer Considered , Dr. Heather Wakelee and Dr. Paul Van Schil join hosts Dr. Narjust Duma and Dr. Stephen Liu to discuss priorities and initiatives for IASLC in the 2021-22 year. Dr. Wakelee takes the reins as President of the IASLC this month during WCLC, the second woman to achieve this honor. Dr. Van Schil begins his term as President-Elect of the IASLC during WCLC, too.

Lung Cancer Considered
ASCO 2021 Highlights with Dr. Heather Wakelee and Dr. Alfredo Addeo

Lung Cancer Considered

Play Episode Listen Later Jun 10, 2021 53:18


The American Society of Clinical Oncology meeting just concluded and Lung Cancer Considered has a summary of the meeting, with a unique lung cancer focus. Tune in as host Stephen Liu and guests Dr. Alfredo Addeo and Dr. Heather Wakelee discuss key findings from ASCO 2021.

Navel Gazing, The Valley Indy Podcast
Does Ansonia Need A Motel On Wakelee Avenue?

Navel Gazing, The Valley Indy Podcast

Play Episode Listen Later Apr 8, 2021 31:09


There are plans to build a motel off Route 8 on Wakelee Avenue in Ansonia. Click play to listen to people react.

Lung Cancer Considered
Women In Thoracic Oncology

Lung Cancer Considered

Play Episode Listen Later Jan 12, 2021 25:13


The latest episode of Lung Cancer Considered discusses women in thoracic oncology and the upcoming IASLC Women in Thoracic Oncology Event. Register now for this event. This episode features a conversation between host, Dr. Narjust Duma, and Dr. Heather Wakelee and Dr. Clarissa Mathias. Dr. Wakelee is a thoracic medical oncologist, Deputy Director of the Stanford Cancer Institute and is the Division Chief of Medical Oncology at Stanford University Medical Center. She is also the president-elect of the IASLC. Dr. Clarissa Mathias, Medical Oncologist at Grupo Oncoclinicas, is president of the Brazilian Society of Medical Oncology, Chair of the ASCO International Committee and a member of the IASLC Board of Directors. Together they discuss their career paths and what they are looking forward to at the Virtual Women in Thoracic Oncology Event hosted by IASLC on January 20th.

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Case Based Panel Discussion - EGFR Mutation Patient Progression and Next Steps

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Play Episode Listen Later Sep 9, 2020 9:12


For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds patient progression in a case with EGFR mutation, and what are the next steps. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Case Based Panel Discussion - EGFR Mutation and High PDL1 - What is the Role of Immunotherapy in Treatment Decisions

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Play Episode Listen Later Sep 2, 2020 5:06


For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds a case with an EGFR Mutation and High PDL1. The discussion centers around the role of immunotherapy in treatment decisions. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Case Based Panel Discussion - EGFR Mutation with MET Amplification Treatment Decisions and the Importance of the Level of MET Amplification

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Play Episode Listen Later Aug 26, 2020 6:52


For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds an EGFR mutation with MET amplification. They review treatment decisions and the importance of the level of MET amplification.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Case Based Panel Discussion - What is the Recommended Treatment for Common EGFR Mutations

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Play Episode Listen Later Jul 29, 2020 6:10


For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this discussion they review the recommended treatment for a common EGFR mutation. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Case Based Panel Discussion - EGFR Mutation Treated with Tagrisso Progression While on Treatment, and What is the Role of Repeat Biopsy

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Play Episode Listen Later Jul 22, 2020 4:37


For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds an EGFR mutation treated with Tagrisso, and progression while on treatment. The doctors also discuss the role of repeat biopsy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Case Based Panel Discussion 3.1 EGFR Mutation - Chemotherapy and an EGFR Inhibitor Concurrently or Sequentially in Treatment Decisions?

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Play Episode Listen Later Jun 24, 2020 8:04


For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations - is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions?For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Case Based Panel Discussion - EGFR Mutation Oligoprogression in Brain and or Body vs Worsening Progression What are the Treatment Options?

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Play Episode Listen Later Jun 24, 2020 5:56


For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations - is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions?For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Lung Cancer Update
Biomarkers Lung 2020 | A Roundtable Discussion Featuring Justin F Gainor, MD, Matthew Gubens, MD, MS, Geoffrey R Oxnard, MD, Heather Wakelee, MD, Isaac Levy, MD and Estelamari Rodriguez, MD, MPH

Lung Cancer Update

Play Episode Listen Later Apr 30, 2020 144:46


A Roundtable Discussion Featuring Justin F Gainor, MD, Matthew Gubens, MD, MS, Geoffrey R Oxnard, MD, Heather Wakelee, MD, Isaac Levy, MD and Estelamari Rodriguez, MD, MPH moderated by Neil Love, MD. Produced by Research To Practice.

Research To Practice | Oncology Videos
Lung Cancer | Heather Wakelee, MD

Research To Practice | Oncology Videos

Play Episode Listen Later Apr 30, 2020 13:13


Biomarker Assessment and Targeted Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC) — Slide Presentation 3: Optimal Approach to Metastatic NSCLC with an EGFR Tumor Mutation After Disease Progression on Osimertinib — Dr Wakelee. CME information and select publications

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Case Based Panel Discussion 2019 3. EGFR Uncommon Exon 20 Mutation - Suggested Treatments Targeted Therapy and Clinica Trial

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Play Episode Listen Later Apr 22, 2020 6:50


For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to an EGFR mutation. In this podcast, the discussion is regarding uncommon EXON 20 mutation, suggested treatments, targeted therapy and clinical trials. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
Case Based Panel Discussion 2019 3.2 EGFR Mutation and the FLAURA Trial, Is There a Difference in Data Based on Demographics

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Play Episode Listen Later Apr 15, 2020 8:28


For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California. In this series, the doctors discuss a series of cases related to EGFR Mutations. For EGFR mutations and the FLAURA trial, is there a difference in data based on demographics and how can that effect treatment decisions? For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Romeo Athletics Radio
Matt Wakelee: Youth Sports, Arts and Crafts, and Olympic Lifting

Romeo Athletics Radio

Play Episode Listen Later Dec 15, 2019 66:52


This week on the podcast we're talking to RA member Matt Wakelee - we talk about his experience in youth sports, his past job as a manager at Michaels, his college experience and his focus on Olympic Weightlifting. Thanks for listening - give us a share, leave us a like/review wherever you listen to podcasts, and let us know what you want to see in future episodes! Romeo Athletics is New England's premier coach-led gym for functional fitness and athletic performance. We're here to help you lose fat, gain muscle, and transform your body into a healthy, head-turning work of art. Learn more about the gym: https://romeoathletics.fitness/ Find us on Instagram: @RomeoAthletics and @EBourcier

Lung Cancer Considered
Women Leaders in Lung Cancer with Dr. Heather Wakelee and Professor Corinne Faivre-Finn

Lung Cancer Considered

Play Episode Listen Later Oct 28, 2019 23:44


Dr. Heather Wakelee thoracic medical oncologist and professor of medicine at Stanford University Medical Center and president-elect of IASLC and Corinne Faivre-Finn professor of thoracic radition oncology at the University of Manchester in the UK and honorary consultant clinical oncologist joined Dr. Jack West at the IASLC World Conference on Lung Cancer in Barcelona, Spain to discuss women leadership in oncology and medicine.

West Wind (Audio)
Dr. Heather Wakelee: Prioritizing Mentorship & Leadership in Thoracic Oncology

West Wind (Audio)

Play Episode Listen Later Jun 7, 2019 30:28


Drs. Heather Wakelee and Jack West review how she entered & became a leader in thoracic oncology, her prioritization of mentorship, & her efforts to continue the strong momentum of the International Association of the Study of Lung Cancer (IASLC).

West Wind (Video)
Dr. Heather Wakelee: Prioritizing Mentorship & Leadership in Thoracic Oncology

West Wind (Video)

Play Episode Listen Later Jun 7, 2019 30:28


Drs. Heather Wakelee and Jack West review how she entered & became a leader in thoracic oncology, her prioritization of mentorship, & her efforts to continue the strong momentum of the International Association of the Study of Lung Cancer (IASLC).

Lung Cancer Considered
IASLC President-Elect Elections: Introducing Candidate Dr. Heather Wakelee

Lung Cancer Considered

Play Episode Listen Later May 30, 2019 21:37


IASLC CEO Dave Mesko sits down with IASLC President-Elect candidate, Dr. Heather Wakelee, Professor of Medicine, Oncology at Stanford University in Stanford, California. Voting is available to active IASLC members and ends at 11:59 Eastern Time on June 26, 2019. Vote at directvote.net/IASLC.

Lung Cancer Update
LCU1 2017 | Interview with Heather Wakelee, MD

Lung Cancer Update

Play Episode Listen Later Sep 20, 2017 63:39


Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Heather Wakelee, MD conducted by Neil Love, MD. Produced by Research To Practice.

Lung Cancer Update
Morbidity and Mortality 2017 Lung | A Roundtable Discussion Featuring Heather Wakelee, MD, Maria Picton, MD and Estelamari Rodriguez, MD, MPH

Lung Cancer Update

Play Episode Listen Later Jul 17, 2017 62:38


ResearchToPractice.com/MorbidityMortality17 - A roundtable discussion featuring Heather Wakelee, MD, Maria Picton, MD and Estelamari Rodriguez, MD, MPH. Moderated by Neil Love, MD. Produced by Research To Practice.

GRACEcast
The Role of Targeted Therapy Post-Resection

GRACEcast

Play Episode Listen Later Apr 6, 2016 4:36


Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

GRACEcast ALL Subjects audio and video
The Role of Targeted Therapy Post-Resection

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 6, 2016 4:36


Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

GRACEcast Lung Cancer Video
The Role of Targeted Therapy Post-Resection

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 6, 2016 4:36


Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.

GRACEcast
What Is a Standard Adjuvant Chemotherapy Regimen?

GRACEcast

Play Episode Listen Later Apr 5, 2016 4:35


Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.

GRACEcast ALL Subjects audio and video
What Is a Standard Adjuvant Chemotherapy Regimen?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 5, 2016 4:35


Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.

GRACEcast Lung Cancer Video
What Is a Standard Adjuvant Chemotherapy Regimen?

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 5, 2016 4:35


Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.

GRACEcast Lung Cancer Video
Why Give Adjuvant Chemotherapy, and to Which Patients?

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 4, 2016 2:26


Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.

GRACEcast ALL Subjects audio and video
Why Give Adjuvant Chemotherapy, and to Which Patients?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 4, 2016 2:26


Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.

GRACEcast
Why Give Adjuvant Chemotherapy, and to Which Patients?

GRACEcast

Play Episode Listen Later Apr 4, 2016 2:26


Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.

GRACEcast Lung Cancer Video
November is Lung Cancer Awareness Month

GRACEcast Lung Cancer Video

Play Episode Listen Later Oct 31, 2015 2:03


Even in the world of lung cancer, there are things to be grateful for. This November, join GRACE as we celebrate them with doctors, patients and caregivers.

GRACEcast ALL Subjects audio and video
November is Lung Cancer Awareness Month

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Oct 31, 2015 2:03


Even in the world of lung cancer, there are things to be grateful for. This November, join GRACE as we celebrate them with doctors, patients and caregivers.

GRACEcast
November is Lung Cancer Awareness Month

GRACEcast

Play Episode Listen Later Oct 31, 2015 2:03


Even in the world of lung cancer, there are things to be grateful for. This November, join GRACE as we celebrate them with doctors, patients and caregivers.

Oncology Nursing Update
ONULung1 2015 | Interview with Heather Wakelee, MD

Oncology Nursing Update

Play Episode Listen Later May 21, 2015 46:12


Clinical Investigator and Nursing Perspectives on the Management of Common Cancers. Lung Cancer Edition. Interview with Heather Wakelee, MD conducted by Neil Love, MD. Produced by Research To Practice.

GRACEcast Lung Cancer Video
An Update on ECOG 1505: Will Avastin (Bevacizumab) Become Standard Treatment for Early Stage Lung Cancer Patients?

GRACEcast Lung Cancer Video

Play Episode Listen Later May 14, 2014 3:55


Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patients are progressing. February 2014.

GRACEcast ALL Subjects audio and video
An Update on ECOG 1505: Will Avastin (Bevacizumab) Become Standard Treatment for Early Stage Lung Cancer Patients?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later May 14, 2014 3:55


Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patients are progressing. February 2014.

GRACEcast
An Update on ECOG 1505: Will Avastin (Bevacizumab) Become Standard Treatment for Early Stage Lung Cancer Patients?

GRACEcast

Play Episode Listen Later May 14, 2014 3:55


Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patients are progressing. February 2014.

GRACEcast Lung Cancer Video
CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

GRACEcast Lung Cancer Video

Play Episode Listen Later May 11, 2014 2:27


Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.

GRACEcast
CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

GRACEcast

Play Episode Listen Later May 11, 2014 2:27


Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.

GRACEcast ALL Subjects audio and video
CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

GRACEcast ALL Subjects audio and video

Play Episode Listen Later May 11, 2014 2:27


Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.

GRACEcast ALL Subjects audio and video
What's the Status and Potential Utility of Cabozantinib in Lung Cancer?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 17, 2014 3:22


Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib - a drug already approved for thyroid cancer - can help patients with lung cancer. February 2014.

GRACEcast Lung Cancer Video
What's the Status and Potential Utility of Cabozantinib in Lung Cancer?

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 17, 2014 3:22


Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib - a drug already approved for thyroid cancer - can help patients with lung cancer. February 2014.

GRACEcast
What's the Status and Potential Utility of Cabozantinib in Lung Cancer?

GRACEcast

Play Episode Listen Later Apr 17, 2014 3:22


Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib - a drug already approved for thyroid cancer - can help patients with lung cancer. February 2014.

GRACEcast Lung Cancer Video
Dr. Heather Wakelee on "Which molecular marker tests do you seek?"

GRACEcast Lung Cancer Video

Play Episode Listen Later Jun 21, 2013 1:27


GRACEcast ALL Subjects audio and video
Dr. Heather Wakelee on "Which molecular marker tests do you seek?"

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jun 21, 2013 1:27


GRACEcast
Dr. Heather Wakelee on "Which molecular marker tests do you seek?"

GRACEcast

Play Episode Listen Later Jun 21, 2013 1:27


GRACEcast Lung Cancer Video
Dr. Heather Wakelee: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

GRACEcast Lung Cancer Video

Play Episode Listen Later May 28, 2013 1:14


Dr. Heather Wakelee, from Stanford University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

GRACEcast
Dr. Heather Wakelee: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

GRACEcast

Play Episode Listen Later May 28, 2013 1:14


Dr. Heather Wakelee, from Stanford University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

GRACEcast ALL Subjects audio and video
Dr. Heather Wakelee: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later May 28, 2013 1:14


Dr. Heather Wakelee, from Stanford University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

GRACEcast
Dr. Heather Wakelee on "My Approach to Maintenance Therapy for Advanced NSCLC"

GRACEcast

Play Episode Listen Later May 17, 2013 2:07


Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

GRACEcast ALL Subjects audio and video
Dr. Heather Wakelee on "My Approach to Maintenance Therapy for Advanced NSCLC"

GRACEcast ALL Subjects audio and video

Play Episode Listen Later May 17, 2013 2:07


Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

GRACEcast Lung Cancer Video
Dr. Heather Wakelee on "My Approach to Maintenance Therapy for Advanced NSCLC"

GRACEcast Lung Cancer Video

Play Episode Listen Later May 17, 2013 2:07


Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

GRACEcast ALL Subjects audio and video
Dr. Heather Wakelee: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 5, 2013 0:54


Dr. Heather Wakelee from Stanford University offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.

GRACEcast
Dr. Heather Wakelee: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

GRACEcast

Play Episode Listen Later Apr 5, 2013 0:54


Dr. Heather Wakelee from Stanford University offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.

GRACEcast Lung Cancer Video
Dr. Heather Wakelee: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 5, 2013 0:54


Dr. Heather Wakelee from Stanford University offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.

Ringler Radio - Structured Settlements and Legal Topics
Ringler's Top Ten on Structured Settlements

Ringler Radio - Structured Settlements and Legal Topics

Play Episode Listen Later Mar 31, 2013 31:26


Even though structured settlements have been around a long time, false impressions about products and services still remain. There are a lot of moving parts involved in a claim's settlement, and lots of financial and legal information swirling around the process. In this podcast, Ringler Radio host Larry Cohen joins colleagues, Jim Early and Bill Wakelee, to debunk the misconceptions sometimes seen in the structured settlement industry, and clarify through their top ten on structured settlements.

GRACEcast
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

GRACEcast

Play Episode Listen Later Mar 25, 2013 1:50


Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

GRACEcast Lung Cancer Video
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 25, 2013 1:50


Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

GRACEcast ALL Subjects audio and video
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Mar 25, 2013 1:50


Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

GRACEcast ALL Subjects audio and video
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Mar 14, 2013 1:15


Dr. Heather Wakelee from Stanford University expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

GRACEcast
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

GRACEcast

Play Episode Listen Later Mar 14, 2013 1:15


Dr. Heather Wakelee from Stanford University expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

GRACEcast Lung Cancer Video
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 14, 2013 1:15


Dr. Heather Wakelee from Stanford University expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

GRACEcast ALL Subjects audio and video
Dr. Heather Wakelee: Do You Use Molecular Marker Information for Management of Earlier Stage Non-Small Cell Lung Cancer?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Feb 25, 2013 1:59


Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have testing for molecular markers, as well as how we might use this information in clinical practice.

GRACEcast Lung Cancer Video
Dr. Heather Wakelee: Do You Use Molecular Marker Information for Management of Earlier Stage Non-Small Cell Lung Cancer?

GRACEcast Lung Cancer Video

Play Episode Listen Later Feb 25, 2013 1:59


Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have testing for molecular markers, as well as how we might use this information in clinical practice.

GRACEcast
Dr. Heather Wakelee: Do You Use Molecular Marker Information for Management of Earlier Stage Non-Small Cell Lung Cancer?

GRACEcast

Play Episode Listen Later Feb 25, 2013 1:59


Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have testing for molecular markers, as well as how we might use this information in clinical practice.

Ringler Radio - Structured Settlements and Legal Topics
The Fiscal Cliff: Impact of the Deal

Ringler Radio - Structured Settlements and Legal Topics

Play Episode Listen Later Jan 21, 2013 29:45


Before the New Year, we did a show on how the fiscal cliff and how it could potentially impact the structured settlement industry and legal clients. Since then, a deal was reached averting a financial crisis for now and has been signed into law by President Obama. In this podcast, Ringler Radio host Larry Cohen and co-host, Bill Wakelee, follow-up with Dr. Christopher Coyne, Economist and Associate Professor of Finance at St. Joseph's University, on the specifics on the fiscal cliff deal, general reaction and its overall impact on Americans and the structured settlement industry.

Lung Cancer Update
LCU1 2012 | Interview with Heather Wakelee, MD

Lung Cancer Update

Play Episode Listen Later Jun 12, 2012 41:57


Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Heather Wakelee, MD conducted by Neil Love, MD. Produced by Research To Practice.

Ringler Radio - Structured Settlements and Legal Topics

Over the past few years we have experienced a financial meltdown, impacting many, including personal injury victims who did not minimize risk. A full economic recovery is slow to come but there are ways to protect your financial future. Ringler Radio, host Larry Cohen along with co-host, Bill Wakelee, talk with returning guest, Dr. Christopher Coyne about how these difficult financial times have affected these unique investors of the structured settlement world. They talk about how structures deal with the volatility of the marketplace and the preservation of capital concept with the structured settlement.

Ringler Radio - Structured Settlements and Legal Topics
The Ringler Productivity Manager (RPM)

Ringler Radio - Structured Settlements and Legal Topics

Play Episode Listen Later May 2, 2011 21:00


The Ringler Productivity Manager (RPM) is a new, efficient platform that the whole company can use to quote all the life companies. On this edition of Ringler Radio, host Larry Cohen welcomes guests, Ringler Associate's RPM guru, Bill Wakelee and Ringler Associate, Cindy Chanley, to take a look at how this new technology is changing the face of structured settlements. Larry, Bill and Cindy explore the ins and outs of RPM, how it benefits colleagues and clients and share their personal experiences with RPM.

Lung Cancer Update for Patients
LCUP1 2009 | Interview with Heather Wakelee, MD

Lung Cancer Update for Patients

Play Episode Listen Later Oct 15, 2009 45:09


ResearchToPractice.com/NLCP2009 – Adjuvant Systemic Treatment of Non-Small Cell Lung Cancer — A Patient and Clinician Education Program on Treatment Options and Ongoing Clinical Trials. Interview with Heather Wakelee, MD conducted by Neil Love, MD. Produced by Research To Practice.

Ringler Radio - Structured Settlements and Legal Topics
The Economy of Structured Settlements

Ringler Radio - Structured Settlements and Legal Topics

Play Episode Listen Later Feb 10, 2009 32:32


In this edition of Ringler Radio, join host, Larry Cohen and co-host, William D. Wakelee, settlement annuity specialist in Ringler's Philadelphia office, as they turn to Dr. Christopher Coyne, Associate Professor in the Department of Finance from Haub School of Business at St. Joseph's University to discuss the state of the economy, the importance of a structured settlement especially now and how we all need to have hope during these hard times.

Ringler Radio - Structured Settlements and Legal Topics

In the world of settlement trusts, one of the advantages is finding a trustee who fully understands the benefits of using structured settlements in trusts and can accommodate the needs of both the claimants and the defendants in each case. In this follow-up to the Trusts and Structured Settlements show, Ringler Radio host, Larry Cohen and co-host, William D. Wakelee, settlement annuity specialist in Ringler's Philadelphia office, welcome back David J. Cover, Senior Vice President and Senior Settlement Advisor for the Trust and Investment Services Division of PeoplesBank, to look inside the settlement trust arena. They will discuss common issues associated with settlement trusts, common reasons for people to put settlement monies into these trusts, how the trust handles the upfront cash that goes into the trust and the structured payments coming in and the education of individuals on the importance of settlement trusts.

Ringler Radio - Structured Settlements and Legal Topics
Personal Injury Victims as a Unique Investor Class Pt III

Ringler Radio - Structured Settlements and Legal Topics

Play Episode Listen Later Mar 17, 2008 31:43


How can the issues that arise in behavioral finance specifically and profoundly affect personal injury victims as members of that unique investor class? Join Ringler Radio host Larry Cohen and co-host, William D. Wakelee from the Ringler office in Philadelphia, as they come full circle in part three of this tremendous series on the unique investor class. Ringler Radio welcomes returning guest, Dr. Christopher Coyne, from St. Joseph's University, who will re-cap by exploring the three concepts within the investment decision-making process, how people behave even after they've decided to take a guaranteed tax-free structured settlement and how unique investors simply can't afford risk.

Ringler Radio - Structured Settlements and Legal Topics

Behavioral finance deals with what academics have seen people do, instead of what people ought to do and is an area of finance that's getting increasing attention among academics and practitioners. Join Ringler Radio host, Larry Cohen and co-host, William D. Wakelee, settlement annuity specialist in Ringler's Philadelphia office, as they discuss the growing area of behavioral finance. Ringler Radio welcomes the expert, Dr. Christopher Coyne of St. Joseph's University, as they explore the behavioral aspects of financial decision, the concept of risk return vs. irrationality, the importance of utility and highlight Dr. Coyne's involvement with studies on behavioral finance.

Ringler Radio - Structured Settlements and Legal Topics
Trusts and Structured Settlements

Ringler Radio - Structured Settlements and Legal Topics

Play Episode Listen Later Dec 10, 2007 39:47


What is a settlement trust and in what cases are they best used? Join Ringler Radio host, Larry Cohen and co-host, William D. Wakelee, settlement annuity specialist in Ringler's Philadelphia office, as they raise the important questions pertaining to settlement trusts. Ringler Radio welcomes David J. Cover, Senior Vice President and Senior Settlement Advisor for the Trust and Investment Services Division of PeoplesBank, to discuss what a settlement trust is, who is most likely to need one, the different types of trusts, how the trust works and the trust's interaction with structured settlements.

Lung Cancer Update
LCU3 2007 | Interview with Heather A Wakelee, MD 03

Lung Cancer Update

Play Episode Listen Later Aug 17, 2007 28:47


www.LungCancerUpdate.com – Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interviews conducted by Neil Love, MD. Produced by Research To Practice.